Tim Chiang
Stock Analyst at Capital One
(1.08)
# 3,517
Out of 4,711 analysts
21
Total ratings
31.25%
Success rate
-7.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Chiang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRTX Heron Therapeutics | Initiates: Overweight | $6 | $1.58 | +279.75% | 1 | Apr 23, 2024 | |
| PTGX Protagonist Therapeutics | Initiates: Overweight | n/a | $41.49 | - | 3 | Oct 30, 2023 | |
| JSPR Jasper Therapeutics | Initiates: Overweight | $70 | $21.57 | +224.52% | 1 | Aug 11, 2023 | |
| AMPH Amphastar Pharmaceuticals | Initiates: Overweight | $44 | $39.14 | +12.42% | 2 | Jul 29, 2022 | |
| KALA KALA BIO | Maintains: Outperform | $300 → $200 | $5.92 | +3,278.38% | 2 | Mar 30, 2022 | |
| PCRX Pacira BioSciences | Maintains: Market Perform | $75 → $66 | $18.98 | +247.73% | 3 | May 5, 2021 | |
| RPTX Repare Therapeutics | Initiates: Outperform | n/a | $1.32 | - | 1 | Oct 28, 2020 | |
| VRCA Verrica Pharmaceuticals | Initiates: Outperform | $21 | $0.69 | +2,925.06% | 1 | Jun 24, 2020 | |
| TEVA Teva Pharmaceutical | Upgrades: Neutral | n/a | $22.09 | - | 6 | Sep 17, 2018 | |
| SMMT Summit Therapeutics | Initiates: Buy | $33 | $17.87 | +84.67% | 1 | Feb 13, 2018 |
Heron Therapeutics
Apr 23, 2024
Initiates: Overweight
Price Target: $6
Current: $1.58
Upside: +279.75%
Protagonist Therapeutics
Oct 30, 2023
Initiates: Overweight
Price Target: n/a
Current: $41.49
Upside: -
Jasper Therapeutics
Aug 11, 2023
Initiates: Overweight
Price Target: $70
Current: $21.57
Upside: +224.52%
Amphastar Pharmaceuticals
Jul 29, 2022
Initiates: Overweight
Price Target: $44
Current: $39.14
Upside: +12.42%
KALA BIO
Mar 30, 2022
Maintains: Outperform
Price Target: $300 → $200
Current: $5.92
Upside: +3,278.38%
Pacira BioSciences
May 5, 2021
Maintains: Market Perform
Price Target: $75 → $66
Current: $18.98
Upside: +247.73%
Repare Therapeutics
Oct 28, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.32
Upside: -
Verrica Pharmaceuticals
Jun 24, 2020
Initiates: Outperform
Price Target: $21
Current: $0.69
Upside: +2,925.06%
Teva Pharmaceutical
Sep 17, 2018
Upgrades: Neutral
Price Target: n/a
Current: $22.09
Upside: -
Summit Therapeutics
Feb 13, 2018
Initiates: Buy
Price Target: $33
Current: $17.87
Upside: +84.67%